SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges
Abstract Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1), programmed cell death ligand-1 (PD-L1), and others have shown potent clinical efficacy and have revolutionized the treatment protocols of a broad spectrum of tumor types, especially non–small-cell lung cancer (NSCLC). De...
Na minha lista:
| Principais autores: | , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMC
2020-07-01
|
| Serier: | Journal of Hematology & Oncology |
| Fag: | |
| Online adgang: | http://link.springer.com/article/10.1186/s13045-020-00940-z |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
